Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Improved anti-fibrotic effects by combined treat- ments of simvastatin and NS-398 in experimental liver fibrosis models

Full metadata record
DC Field Value Language
dc.contributor.authorKang, Seong Hee-
dc.contributor.authorYim, Hyung Joon-
dc.contributor.authorHwang, Ji-won-
dc.contributor.authorKim, Mi-jung-
dc.contributor.authorLee, Young-Sun-
dc.contributor.authorJung, Young Kul-
dc.contributor.authorYim, Hyungshin-
dc.contributor.authorKim, Baek-Hui-
dc.contributor.authorPark, Hae-Chul-
dc.contributor.authorSeo, Yeon Seok-
dc.contributor.authorKim, Ji Hoon-
dc.contributor.authorYeon, Jong Eun-
dc.contributor.authorUm, Soon Ho-
dc.contributor.authorByun, Kwan Soo-
dc.date.accessioned2022-12-20T05:53:51Z-
dc.date.available2022-12-20T05:53:51Z-
dc.date.issued2022-07-
dc.identifier.issn1226-3303-
dc.identifier.issn2005-6648-
dc.identifier.urihttps://scholarworks.bwise.kr/erica/handle/2021.sw.erica/111376-
dc.description.abstractBackground/Aims: Efficient anti-fibrotic therapies are required for the treatment of liver cirrhosis. Hydroxymethylglu-taryl-coenzyme A reductase inhibitors (statins) and cyclooxygenase-2 (COX-2) inhibitors have been reported to have anti -fi-brotic effects. Here, we investigated whether combined treatment with a statin and a COX-2 inhibitor has synergistic anti -fi-brotic effects. Methods: The effects of treatment strategies incorporating both simvastatin and a COX-2 inhibitor, NS-398, were inves-tigated using an immortalized human hepatic stellate cell line (LX-2) and a hepatic fibrosis mouse model developed using thioacetamide (TAA) in drinking water. Cellular proliferation was investigated via 5-bromo-2-deoxyuridine uptake. Pro-and anti-apoptotic factors were investigated through Western blotting and real-time polymerase chain reaction analysis. Results: The evaluation of the anti-proliferative effects on LX-2 cells showed that the observed effects were more pro-nounced with combination therapy than with single-drug therapy. Moreover, hepatic fibrosis and collagen deposition de-creased significantly in TAA-treated mice in response to the combined treatment strategy. The mechanisms underlying the anti-fibrotic effects of the combination therapy were investigated. The effects of the combination therapy were correlated with increased expression levels of extracellular signal-regulated kinase 1/2 signaling molecules, upregulation of the Bax/Bcl-2 signaling pathway, inhibition of the transforming growth factor-13 signaling pathway, and inhibition of tissue inhibitor of matrix metalloproteinases 1 and 2. Conclusions: The combination of simvastatin and NS-398 resulted in a synergistic anti-fibrotic effect through multiple pathways. These findings offer a theoretical insight into the possible clinical application of this strategy for the treatment of advanced liver diseases with hepatic fibrosis.-
dc.format.extent18-
dc.language영어-
dc.language.isoENG-
dc.publisherKOREAN ASSOC INTERNAL MEDICINE-
dc.titleImproved anti-fibrotic effects by combined treat- ments of simvastatin and NS-398 in experimental liver fibrosis models-
dc.title.alternativeImproved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models-
dc.typeArticle-
dc.publisher.location대한민국-
dc.identifier.doi10.3904/kjim.2021.138-
dc.identifier.scopusid2-s2.0-85134082707-
dc.identifier.wosid000822778300006-
dc.identifier.bibliographicCitationKOREAN JOURNAL OF INTERNAL MEDICINE, v.37, no.4, pp 745 - 762-
dc.citation.titleKOREAN JOURNAL OF INTERNAL MEDICINE-
dc.citation.volume37-
dc.citation.number4-
dc.citation.startPage745-
dc.citation.endPage762-
dc.type.docTypeArticle-
dc.identifier.kciidART002849289-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.description.journalRegisteredClasskci-
dc.relation.journalResearchAreaGeneral & Internal Medicine-
dc.relation.journalWebOfScienceCategoryMedicine, General & Internal-
dc.subject.keywordPlusGROWTH-FACTOR-BETA-
dc.subject.keywordPlusHEPATIC-FIBROSIS-
dc.subject.keywordPlusINHIBITION-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordPlusAPOPTOSIS-
dc.subject.keywordPlusCELLS-
dc.subject.keywordPlusPROLIFERATION-
dc.subject.keywordPlusREVERSIBILITY-
dc.subject.keywordPlusMITOCHONDRIA-
dc.subject.keywordPlusFIBROGENESIS-
dc.subject.keywordAuthorLiver cirrhosis-
dc.subject.keywordAuthorHydroxymethylglutaryl-CoA reductase inhibitors-
dc.subject.keywordAuthorCyclooxygenase 2 inhibitors-
dc.subject.keywordAuthorHepatic stellate cells-
dc.identifier.urlhttps://www.kjim.org/journal/view.php?doi=10.3904/kjim.2021.138-
Files in This Item
Go to Link
Appears in
Collections
COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyungshin photo

Yim, Hyungshin
COLLEGE OF PHARMACY (DEPARTMENT OF PHARMACY)
Read more

Altmetrics

Total Views & Downloads

BROWSE